COVID-19 Antibody Assay testing

In response to the global COVID-19 pandemic, LGC’s Immunogenicity Centre of Excellence have developed and validated a serological test for the detection of antibody responses to COVID-19 in serum and dried blood collection (Neoteryx Mitra® using an electrochemiluminescence semi-homogenous bridging assay).

UPDATE: We are pleased to announce LGC’s Covid-19 antibody assay now holds CE Mark and has ISO17025 accreditation applied for.

  • Microsamples are taken remotely without the need for professional healthcare workers.
  • Our assay is suitable for both serum and dry blood sampling using Neoteryx’s Mitra® device.

Click here for more information.

 

If you are looking to assess therapies for drug efficacy against COVID-19 we can offer our drug development solutions. Our experiences include the Bioanalysis of potential antiviral agents such as:

  • Monoclonal antibody therapeutics
  • Protease inhibitors
  • Antiviral/Antiretrovirals
  • Antimalarials
  • RNA polymerase inhibitors

 

COVID-19: We are here to help

Our entire Drug Development Solutions operation has now moved to shift working which means we are open from 7am to 8pm.

Decontamination between shifts by our staff and specialist cleaners.

We have time/flexibility and resource to ensure our contracted studies remain on track, as well as help where studies (that have not been contracted to LGC) may be at risk.

For full details on our business contingency during the pandemic click here.

If you have a need to develop/transfer and validate methods for future studies or act as a back-up for at risk studies, please contact us.